Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed stage III or IV metastatic melanoma
Unresectable disease for which no other therapy exists Measurable or evaluable disease by
clinical or radiographic evaluation Metastatic tumor tissue expressing both gp100 and
MART-1 No uncontrolled or progressive CNS involvement

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:
Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 No
clinically significant hematologic disorder Hepatic: Bilirubin less than 2.0 mg/dL No
clinically significant hepatic disease Hepatitis B surface antigen negative Renal:
Creatinine less than 2.0 mg/dL No clinically significant renal disease Cardiovascular: No
clinically significant cardiac disease Other: Not pregnant or nursing Fertile patients
must use effective contraception Negative pregnancy test HIV-1 and HIV-2 negative HTLV-1
negative No significant psychiatric disorder that would prevent compliance No underlying
condition that would preclude study therapy No autoimmune disease or other major immune
system illness No active infection requiring parenteral antibiotic therapy

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy with vaccines directed
at MART-1 or gp100 melanoma antigens Prior interleukin-2 or interferon therapy allowed
Chemotherapy: At least 4 weeks since prior chemotherapy and recovered No concurrent
chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior
radiotherapy and recovered Surgery: At least 4 weeks since prior surgery (except study
biopsies) and recovered Other: At least 4 weeks since prior experimental therapy and
recovered At least 4 weeks since prior immunosuppressive drugs and recovered No other
concurrent experimental therapy or anti-cancer drugs No concurrent immunosuppressive
therapy